Original ArticleNon–Small Cell Lung CancerEarly Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
Non–Small Cell Lung Cancer
Under an Elsevier user license
open archive
Keywords
Immune checkpoint inhibitor
Immune-related adverse event
Nivolumab
Non–small cell lung cancer
Programmed cell death ligand 1
Cited by (0)
Readers of this article may receive CME credit. Further information can be found at https://www.iaslc.org/journal-based-cme.
Drs. Teraoka and Fujimoto contributed equally to this work.
Disclosure: Dr. Fujimoto reports personal fees from Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb K.K. outside the submitted work. The remaining authors declare no conflict of interest.
Trial registration: UMIN000022037.
© 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc.